Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
19 March 2019
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards. The chosen world-class research teams are leading the charge towards a cancer free future by investigating new ways to diagnose and treat the disease.
Melanoma Institute Australia researchers, including Co-Medical Directors Professor Georgina Long and Professor Richard Scolyer, Associate Professor Matteo Carlino and Dr James Wilmott, have been awarded Cancer Council NSW Funding of $425,095 over the 2019-2021 funding period. Dr Wilmott attended the Gala Dinner on Thursday, March 14 to formally accept the grant on behalf of Melanoma Institute Australia.
Melanoma of the skin is the fourth most common cancer in Australia, with over 15,000 people expected to be diagnosed with the disease in 2019. Unlike other cancers of the skin, melanoma can spread throughout the body if not treated early. Termed ‘metastatic melanoma’ this advanced form of the disease kills one Australian every 5 hours.
Once melanoma has spread, the most effective treatment is immunotherapy. These immunotherapies release the brakes on the immune system to attack tumour cells. However, more than 40% of metastatic melanoma patients are not cured with these therapies, more for the other cancers. Therefore doctors need to be able to identify who is or isn’t likely to have benefit from the treatment. This means precious time is lost before alternative treatments are offered to those patients for whom immunotherapy won’t be effective.
Dr Wilmott is part of a team of researchers focused on finding treatments for the more than 40% of patients that are not cured with our best current therapies. In another study funded by Cancer Council NSW early career fellowship, the team of oncologists, pathologists, scientists and statisticians identified a set of immune related genes that are critical for a melanoma patient’s response to immunotherapies. The team have initially used these genes to successfully predict the effectiveness of immunotherapy in 105 patients with advanced melanoma.
In this project, the team aim to translate this information from the laboratory into the clinics of their oncology team, giving them the opportunity to test their methods in over 400 patients. They hope to verify their test can accurately identify patients who will respond to standard immunotherapies and the patients for who should be offered alternative treatment options.
This study could lead to the introduction of a simple test in the earliest stages of treatment planning for patients who are diagnosed with advanced melanoma. This would provide critical information for decision-making and ensure patients are offered the treatments most likely to be effective against their cancer.
This was adapted from the article originally published on Cancer Council NSW.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
A round of applause for a well deserved win.
A message from our CEO, Carole Renouf
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.